Simultaneous Assay for Multiple Pathogens in Blood (SAMP-B)

血液中多种病原体的同时检测 (SAMP-B)

• 批准号: 7744078
• 负责人: Gao Chen
• 金额: $ 20万
• 依托单位: MAXWELL SENSORS, INC.
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-08-03 至 2010-08-02
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7744078
• 关键词: Adopted; Antibodies; Automation; Bar Codes; Beds; Biological Assay; Birds; Blood; Blood Banks; Blood donor; Blood donor screening; Blood-Borne Pathogens; Clinical; Detection; Development; Diagnostic; Disease; Donor Selection; Drops; Equilibrium; Evaluation; Figs - dietary; Fluorescence; Goals; HIV; Hepatitis B; Hepatitis B Virus; Hepatitis C; Hepatitis C virus; Human; Individual; Infection; Laboratories; Magnetic Bead Technology; Magnetism; Molecular; Molecular Profiling; Nucleic Acid Amplification Tests; Nucleic Acid Probes; Operative Surgical Procedures; Patients; Performance; Persons; Polymers; Process; Property; Protocols documentation; Reaction; Resolution; Sampling; Screening procedure; Semiconductors; Sensitivity and Specificity; Specimen; Syphilis; System; Technology; Testing; Tetanus Helper Peptide; Time; Training; Variant; Viral; Virus; West Nile virus; base; cost; design; design and construction; digital; flexibility; fluorophore; helicase; indium arsenide; magnetic beads; pathogen; prevent; public health relevance; sensor

DESCRIPTION (provided by applicant): The recent development of commercially-available assays using nucleic acid amplification test technologies (NAT) have made it possible for blood centers to consider applying these tests to blood donor screening. But NAT test systems, so far, are time intensive, require restricted laboratory space and highly-trained technical staff, and generally are unsuited to large-scale screening of donor samples. U.S. blood centers have adopted two basic "pooling and pool resolution" strategies. One is a straight pool of 24 in which resolution of a "reactive pool" requires testing individual samples. In the other strategy, smaller (intermediate) pools are prepared and combined to create a final (master) pool. Resolution of reactive master pools occurs by first testing the intermediate pools and then, if necessary, the individual samples. Pool size and pooling strategy balance assay sensitivity with the practical demands of assuring blood availability. Maxwell Sensors, Inc. (MSI) proposes to combine Helicase-Dependent Amplification (HDA) and Digital Magnetic Bead (DM-Bead) technologies to produce a one sample rapid, Simultaneous Assay for Multiple Pathogens in Blood (SAMP-B), in a high throughput 96-well microplate format. With a few drops of a donor's blood combined with DM-beads in a single microwell, it is possible to simultaneously identify HIV type 1 and 2, Hepatitis B (HBV), Hepatitis C (HCV), Human T- Lymphotropic Virus (HTLV type I and II), West Nile Virus (WNV), and many other blood-borne diseases. The DM-Bead, mass fabricated with digital bar codes by photolithography, then tagged with nucleic acid probes, are able to accurately identify many targets in a single homogeneous medium. The combined technology is very powerful and offers the following advantages: Sample pooling is not necessary: screening for multiple pathogens can be performed on an individual person's sample. Small quantity of sample: a few drops of blood in a microwell are all that's needed to identify multiple target pathogens. It not only determines a reactive sample, but also identifies "reactive to what". Reduced window period: HDA offers high sensitivity and specificity without the "window period" associated with antibody based screening technologies. Rapid and high throughput: simple isothermal operation and 96 patient samples can be performed on a single 96-well microplate. Flexibility: easy addition of new probes for additional screening targets on beads. Low cost, easy to use, and high reliability: DM-beads are low cost, simple operation steps, and batch to batch variation is minimal. During this project, we will focus on four key tasks: 1) design and fabrication of digital magnetic barcode beads, 2) design and construction of a detection system, 3) testing the DM-Bead-based multiplex HDA assay and 4) evaluation of system and bioassay performance. PUBLIC HEALTH RELEVANCE: Maxwell Sensors Inc. (MSI) proposes to develop a helicase-dependent amplification-based system, using digital magnetic barcoded beads that provide rapid, accurate, and easy-to-use screening for multiple blood-borne pathogens in small specimens of donor blood. This Simultaneous Assay for Multiple Pathogens in Blood will help blood banks and clinical laboratories to quickly test very large volumes of donated blood, and will help prevent the spread of blood-borne infections. The proposed technology that marries an advanced semiconductor fabrication process with molecular signature amplification and probing will allow high-throughput molecular diagnostic profiling of individuals at relatively low cost.

描述（由申请人提供）：最近使用核酸扩增测试技术（NAT）的商业可用分析的发展使血液中心有可能考虑将这些测试应用于献血者筛选。但是到目前为止，NAT测试系统是时间密集型的，需要有限的实验室空间和训练有素的技术人员，而且通常不适合大规模筛选供体样本。美国血液中心采用了两种基本的“池和池解决”策略。一种是24个的直池，其中“反应池”的分辨率需要测试单个样品。在另一种策略中，准备并组合较小的（中间）池以创建最终（主）池。通过首先测试中间池，然后（如有必要）测试单个样本，可以解决反应性主池的问题。池大小和池策略平衡分析敏感性与确保血液可用性的实际需求。